COVID-19 Clinical Trial
Official title:
Evaluation of the Immune Response to SARS-CoV-2 Among Patients With Covid-19 in Costa Rica
Describe the immune response of patients affected by SARS-CoV-2, including an assessment of
the types of antibodies elicited by the infection, specifc antibody titers for the different
isotypes, evolution of the antibody response over time, protective efficacy and immune
correlates of protection.
investigate genetic determinants of Covid-19 and of the imune response to this condition.
Finally, the study will investigate secondary infection rate and its determinants among
household contacts of Covid-19 patients.
The main objective of the study is to describe the immune response to the SARS-CoV-2 virus
among patients with confirmed Covid-19 disease in terms of antibody levels, differences in
response related to epidemiologic and clinical characteristics, duration of the antibody
response and protective efficacy.
Of particular interest is the demonstration of seroconversion with neutralizing antibodies,
their duration during a follow-up of two years and their ability to prevent subsequent
infections and disease. If antibodies are demonstrated to protect against subsequent
infections and that protection is long-lasting, this can be instrumental for the
reincorporation of immune individuals into normal life and economic activities.
Additional secondary objectives include determination of population-prevalence of past
infection and assessment of genetic determinants of the immune response and the clinical
presentation of the disease. Finally, we will investigate secondary transmission in a sample
of household contacts of Covid-19 cases.
This study will provide important information to define the use of specific types of
antibodies and their potential utility for diagnosis, ascertainment of previous exposure and
acquired immunity. The effort is being conducted by the Caja Costarricense de Seguro Social,
the Costa Rican Ministry of Health and the Agencia Costarricense de Investigaciones
Biomédicas (ACIB), in collaboration with the US National Cancer Institute, the US National
Institute of Allergy and Infectious Diseases and the German Cancer Research Center and will
be supervised by the Ethical Committee of the CCSS according to local regulations.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
| Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
| Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
| Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
| Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
| Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
| Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
| Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
| Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
| Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
| Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
| Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
| Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
| Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
| Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
| Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|